• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion.

作者信息

Berg S L, Cowan K H, Balis F M, Fisherman J S, Denicoff A M, Hillig M, Poplack D G, O'Shaughnessy J A

机构信息

Pediatric Branch, National Cancer Institute, Bethesda, MD 20892.

出版信息

J Natl Cancer Inst. 1994 Jan 19;86(2):143-5. doi: 10.1093/jnci/86.2.143.

DOI:10.1093/jnci/86.2.143
PMID:7903702
Abstract
摘要

相似文献

1
Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion.
J Natl Cancer Inst. 1994 Jan 19;86(2):143-5. doi: 10.1093/jnci/86.2.143.
2
Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer.多柔比星与紫杉醇给药间隔对局部晚期乳腺癌患者体内这些药物药代动力学的影响。
Cancer Chemother Pharmacol. 2001 Oct;48(4):333-7. doi: 10.1007/s002800100297.
3
Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity.表柔比星与紫杉醇序贯治疗对药代动力学及毒性的影响
J Clin Oncol. 2000 May;18(10):2116-25. doi: 10.1200/JCO.2000.18.10.2116.
4
Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.乳腺癌患者中多柔比星与紫杉醇相互作用的人体药代动力学特征及体外研究
J Clin Oncol. 1997 May;15(5):1906-15. doi: 10.1200/JCO.1997.15.5.1906.
5
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.在一项针对转移性乳腺癌患者的紫杉醇和多柔比星的I期研究中，紫杉醇对多柔比星药代动力学的序列依赖性改变。
J Clin Oncol. 1996 Oct;14(10):2713-21. doi: 10.1200/JCO.1996.14.10.2713.
6
Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience.紫杉醇治疗转移性乳腺癌：MD安德森癌症中心的经验
Semin Oncol. 1995 Jun;22(3 Suppl 6):101-4.
7
Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.最新消息：MD安德森癌症中心使用紫杉醇治疗乳腺癌的经验。
Semin Oncol. 1995 Aug;22(4 Suppl 8):9-15.
8
Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer.
Semin Oncol. 1994 Oct;21(5 Suppl 8):19-23.
9
Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer.转移性乳腺癌患者使用粒细胞集落刺激因子联合72小时输注紫杉醇和阿霉素的I/II期研究
J Clin Oncol. 1996 Mar;14(3):774-82. doi: 10.1200/JCO.1996.14.3.774.
10
Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.
J Clin Oncol. 1999 Mar;17(3):880-6. doi: 10.1200/JCO.1999.17.3.880.

引用本文的文献

1
miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression.微小RNA-495通过抑制多药耐药蛋白1（MDR1）的表达，使多药耐药癌细胞对阿霉素和紫杉醇的联合用药敏感。
J Cell Mol Med. 2017 Sep;21(9):1929-1943. doi: 10.1111/jcmm.13114. Epub 2017 Apr 14.
2
Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group.柔红霉素在儿童中的药代动力学和药物基因组学：来自儿童肿瘤学组的报告。
Cancer Chemother Pharmacol. 2014 Oct;74(4):831-8. doi: 10.1007/s00280-014-2535-4. Epub 2014 Aug 14.
3
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
紫杉醇与表柔比星联合化疗在乳腺癌患者中的药代动力学和药效学
Br J Clin Pharmacol. 2002 May;53(5):508-18. doi: 10.1046/j.1365-2125.2002.01579.x.
4
A phase II trial of paclitaxel and epirubicin in advanced breast cancer.一项关于紫杉醇和表柔比星用于晚期乳腺癌的II期试验。
Br J Cancer. 2000 Aug;83(4):438-42. doi: 10.1054/bjoc.2000.1306.
5
A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer.
Invest New Drugs. 1999;17(1):73-80. doi: 10.1023/a:1006219601797.
6
Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.癌症患者蒽环类药物和紫杉醇治疗方案的药代动力学优化
Clin Pharmacokinet. 1999 Sep;37(3):195-211. doi: 10.2165/00003088-199937030-00002.
7
The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.人类细胞色素P450酶在抗癌药物代谢中的作用：对药物相互作用的影响。
Br J Clin Pharmacol. 1995 Dec;40(6):523-30. doi: 10.1111/j.1365-2125.1995.tb05796.x.
8
Clinical pharmacokinetics of paclitaxel.紫杉醇的临床药代动力学
Clin Pharmacokinet. 1994 Oct;27(4):256-69. doi: 10.2165/00003088-199427040-00002.
9
Current status of paclitaxel in the treatment of breast cancer.紫杉醇在乳腺癌治疗中的现状
Breast Cancer Res Treat. 1995;33(1):27-37. doi: 10.1007/BF00666068.
10
Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.紫杉醇。其药效学和药代动力学特性以及在癌症治疗中的治疗潜力综述。
Drugs. 1994 Nov;48(5):794-847. doi: 10.2165/00003495-199448050-00009.